RESEARCHPAPER
HumanVaccines&Immunotherapeutics11:8,2102--2112;August2015;©2015TaylorandFrancisGroup,LLC
Influenza vaccination in children primed with
(cid:1)
MF59 -adjuvanted or non-adjuvanted seasonal
influenza vaccine
TimoVesikari1,AinoForst(cid:1)en1,AshwaniArora2,*,TheodoreTsai2,andRalfClemens2
1UniversityofTampereMedicalSchool;Tampere,Finland;2NovartisVaccinesandDiagnosticsInc.;Cambridge,MAUSA
Keywords:adjuvant,influenza,MF59,pediatric,revaccination,seasonalvaccine
Abbreviations:AE,adverseevent;aTIV,MF59-adjuvantedtrivalentinactivatedinfluenzavaccine;CBER,CenterforBiologicsEvalu-
ation&Research;CHMP,EuropeanCommitteeforMedicinalProductsforHumanUse;FAS,fullanalysesset;HI,hemagglutina-
tioninhibition;CI,confidenceinterval;LAIV,live-attenuatedinfluenzavaccine;GMR,geometricmeanratio;GMT,geometricmean
titer;HI,hemagglutinationinhibition;TIV,trivalentinactivatedinfluenzavaccine;SAE,seriousadverseevent;SD,standarddeviation
Routine annual influenza immunization is increasingly recommended in young children. We compared the safety
andimmunogenicityofvaccinationwithtrivalentinactivatedinfluenzavaccine(TIV)versusMF59-adjuvantedTIV(aTIV)
in children who received 2 half or full doses of aTIV or TIV, or non-influenza control vaccine, in an efficacy trial
conducted2yearsearlier.197healthychildrenaged30–96monthswererandomizedtoreceivevaccinationwithaTIV
orTIVin2010.Toevaluateresponsestothefirstfollow-upseasonalvaccinationafterprimingweexcludedchildrenwho
receivedinfluenzavaccine(s)inthe2009pandemicyearleaving40childrenvaccinatedwithaTIV,26childrenwithTIV
and 10 children with aTIV after a control vaccine in the parent study. Hemagglutination inhibiting antibodies were
assayedonDays1,22and181.aTIVvaccinationproduced6.9to8.0-foldhigherantibodyresponsesthanthereference
TIV-TIVregimenagainstA/H3N2andBstrains,whichremainedhigher6 monthsfollowingvaccination.Theresponseto
theB/Victorialineageantigeninthesecondyear’svaccine(thefirstvaccinecontainedaB/Yamagatalineageantigen)
demonstratedthataTIVprimedforanadequateresponseafterasingledoseonDay22(GMTs160,95toantigensin
the 2 lineages, respectively), whereas TIV did not (GMTs 38, 20). Vaccination with aTIV produced slightly higher but
acceptablelocalandsystemicreactogenicitycomparedtoTIV-TIVandTIV-aTIVmixedregimens.Withinthelimitations
ofasmallstudy,thestrongimmuneresponsessupporttheuseofaTIVforvaccinationinyoungchildren.
Introduction cannot be used in children under 5 years of age who have a his-
tory of wheezing, and not at all in children under 24 months of
Routineannualinfluenzaimmunizationofchildrenisrecom- age.7,10
mended in the USA and Finland where nearly half of children The use of adjuvantssuch as MF59 cansignificantly enhance
whoarehospitalizedforinfluenzawerepreviouslyhealthy,with- the immune response in previously unvaccinated children, with
out recognized risk factors.1-5 Similarly, 40% of fatal influenza protectiveantibodieslevelsbeingachievedearlierandlastinglon-
cases in children occur in previously healthy children.6 These ger than with non-adjuvanted TIV.11,12 MF59 also stimulates a
characteristics of pediatric influenza support the universal use of broaderimmuneresponsethatmayprovideforincreasedefficacy
influenza vaccine in children at an early age with annual against heterovariant strains.13-15 MF59(cid:1) (Novartis Vaccines)
revaccinations. wasthefirstoil-in-wateremulsionadjuvantincludedinalicensed
Although the medical need for routine influenza immuniza- vaccine, the adjuvanted seasonal TIV (aTIV) indicated for older
tioninchildrenisclear,availablevaccineshavelimitations;triva- adults(Fluad(cid:1) NovartisVaccines).16,17
lent inactivated influenza vaccines (TIV) have less than optimal Wepreviouslydemonstratedinaheadtoheadtrialinvaccine-
efficacy and live-attenuated influenzavaccine (LAIV) has restric- na€ıve 6–71 month old children (conducted principally in the
tionsforchildrenunder24 monthsyearsofagebecauseofsafety 2007–2008 season) that aTIV had 86% efficacy in preventing
concerns.7–9 While TIV may be »40–60% efficacious in chil- laboratory-confirmedinfluenzawhileconfirminginthesametrial
dren under 6 years old, there is no clear evidence for efficacy in the modest efficacy of TIV, at 42%.11 This phase 3b extension
the youngest age group, 6–23 month-olds.8,9 LAIV has been study was conducted to assess the safety and immunogenicity of
(cid:1)
shown to be more efficacious than TIV in 2–7 year-olds, but vaccinationwithaTIVvs.TIV(Agrippal ,NovartisVaccines)in
*Correspondenceto:AshwaniArora;Email:ashwani_kumar.arora@novartis.com
Submitted:11/07/2014;Revised:04/03/2015;Accepted:04/19/2015
http://dx.doi.org/10.1080/21645515.2015.1044167
2102 HumanVaccines&Immunotherapeutics Volume11Issue8
children from the previous efficacy trial, now at 30– 96 months Finland with narcolepsy associated with an AS03-adjuvanted
ofage.11The2009H1N1pandemicpreventedusfromevaluat- H1N1 vaccine that was used in several European countries
ingthevaccinationresponseintheseasonimmediatelyfollowing includingFinlandduringthe2009H1N1influenzapandemic.18
the efficacy trial. All subjects who received either seasonal or In total, 197 subjects were enrolled and were categorized into
monovalent pandemic vaccine in 2009 were excluded in this 2 age cohorts, 6 -< 36 months (n D 29) and 36 -< 96 months
studyanalysis,inordertomoreclearlydemonstratetheimmune (nD168).Theyoungeragegroupwastoosmalltodrawconclu-
responseofre-vaccinationinthefirstfollow-upseasonalvaccina- sions on the immune response sothe age cohorts were combined
tionafterpriming.Thevaccinestrainsin2010–2011[A/Califor- andresultsweregroupedbyvaccinereceived.Ofthe197subjects
nia/7/2009(H1N1),A/Perth/16/2009(H3N2)andB/Brisbane/ that were enrolled and randomized to receive aTIV (n D 135)
60/2008(Victoria)]wereantigenicallydistinctfromthoseinthe andTIV(nD62),188completedthestudy.Reasonsforprema-
priming vaccine in 2008–2009 [A/Brisbane/59/2007 (H1N1), ture withdrawal were withdrawal of consent (N D 4) and loss to
A/Brisbane/10/2007 (H3N2), and B/Florida/4/2006 (Yama- follow-up (N D 5) (Fig. 1). To more clearly demonstrate the
gata)], providing us with the opportunity to examine prime to immune responses to vaccination in follow-up seasonal vaccina-
boost responses in young children following a change in B anti- tion after priming, all subjects who received influenza vaccine in
gens,fromB/YamagatalineagetoB/Victorialineagestrain. 2009, seasonal or monovalent pandemic, were excluded from the
immunogenicityandsafetyanalysespresentedinthisreport.Ulti-
mately, 40 children revaccinated with aTIV, 26 children revacci-
Results nated with TIV, and 10 control children receiving influenza
vaccine for the first time (and were administered aTIV) were
Subjects includedintheanalysesforthisstudy(Fig. 1).
Fewer subjects were enrolled in the extension study than the The baseline demographic characteristics of the enrolled sub-
originally planned 1970 subjects, due to parental concerns in jects by priming and subsequent vaccines are presented in
Figure1.Studyflow.
www.tandfonline.com HumanVaccines&Immunotherapeutics 2103
Table1.StudypopulationdemographicsbyprimingvaccineintheoriginalefficacystudyandvaccinationwithaTIVorTIV
PrimingVaccine aTIV(nD29) TIV(nD37) Control(nD10)
RevaccinationVaccine aTIV(nD17) TIV(nD12) aTIV(nD23) TIV(nD14) aTIV(nD10)
Age,mean§SD,months 58.2§22.6 62.6§21.1 64.8§21.3 67.4§16.7 64.6§18.7
Male(%) 53 50 52 14 30
Race(%)
Caucasian 100 100 96 86 90
Hispanic 0 4 7
Other 0 1 10
Weight§SDweight,kg 19.8§5.9 20.5§4.9 19.8§4.3 20.1§3.2 21.7§4.6
Height§SDheight,cm 109.5§14.7 111.7§12.9 112.0§13.1 114.3§10.4 115.4§12.7
MetStudyCriteria(%) 100 100 100 100 100
TIV:trivalentinactivatedinfluenzavaccines,aTIV:MF59adjuvantedTIV,SD:standarddeviation.
Childrenvaccinatedwithnon-influenzacontrolduringparentstudyonlyreceivedaTIVintheextensionstudy.
Table 1. Vaccine groups were comparable with respect to age, primedwithTIVandrevaccinatedwithTIVandthosewhopre-
body size characteristics, and the majorityof study subjects were viouslyreceivedthecontrolnon-influenzavaccinesandwerevac-
Caucasian.Therewasahigherproportionofgirlsinthechildren cinatedwithaTIV.
Figure2.Homologousantibodyresponsesinchildren30-<96monthsoldvaccinatedwithaTIVorTIV,byprimingvaccine.DashedlinesindicatesCom-
mitteeforMedicinalproductsforHumanUse(CHMP)criterion;thepercentageofsubjectsachievingseroprotection(HIantibodytiter(cid:2)40)shouldbe
>70%,thepercentageofsubjectsachievingseroconversionshouldbe(cid:2)40%andgeometricmeanratioshouldbe>2.5.Noneofthesubjectswerevac-
cinatedwithseasonalorpandemicvaccinein2009.Childrenvaccinatedwithnon-influenzacontrolduringparentstudyonlyreceivedaTIVintheexten-
sionstudy.
2104 HumanVaccines&Immunotherapeutics Volume11Issue8
Immunogenicityanalyses metbothCBERcriteriaforseroconversionandseroprotectionat
EvaluationofimmunogenicitycriteriaaccordingtoEuropean Day22(Fig. 2).
Committee for Medicinal Products for Human Use (CHMP) Percentages of subjects achieving a more stringent cut-off
criteriaispresentedinFigure 2.Subjectswhowereprimed with criterion hemagglutination inhibition (HI) titer (cid:2)110 are pre-
aTIV and TIV andvaccinated with aTIVin the extension study sented in Figure 3. In children primed with aTIV, HI titers
metall3CHMPcriteriaforseroprotection(>70%),seroconver- (cid:2)110 at Day 22 were achieved in 94% (A/H1N1), 100% (A/
sion (>40%) and geometric mean ratio (GMR) (>2.5) against H3N2) and 69% (B/Brisbane/60/2008) after vaccination with
the 3 homologous strains with persistence up to 6 months fol- aTIV and 75% (A/H1N1), 100% (A/H3N2) and 58% (B/
lowingvaccination.SubjectswhowereprimedwithTIVandvac- Brisbane/60/2008) following vaccination with TIV. In TIV-
cinated with aTIV or TIV in the extension study met all 3 primed children, the proportion achieving HI titres of (cid:2)110
CHMP criteria against A/California/7/2009 (A/H1N1) and A/ were 91%, 100% and 22% (vaccination aTIV) and 100%,
Perth/16/2009 (A/H3N2) and 2 out of 3 criteria (vaccination 71% and 0% (vaccination TIV) against A/H1N1, A/H3N2
aTIV) and 1 out of 3 criteria (vaccination TIV) against B/Bris- and B strains, respectively. In children previously vaccinated
bane/60/2008 (Victoria). Children who were previously vacci- with non-influenza control and vaccinated with aTIV, 89%
nated with non-influenza control vaccine and vaccinated with achieved a titer (cid:2)110 to A/H1N1, 100% to H3N2 and 33%
aTIVmetallCHMPcriteriaexceptforseroprotectionagainstB/ to B/Brisbane/60/2008 (Victoria lineage).
Brisbane/60/2008 (Victoria) at Day 22. When using Center for Day 181 HI titers (cid:2)110 were achieved in 24–100% and
Biologics Evaluation & Research (CBER) criteria, only the sub- 8–100% in children after vaccination with aTIV and TIV,
jects who were primed with aTIV and revaccinated with aTIV respectively (Fig. 3).
Figure3.PercentagesofsubjectswithHIantibodytiters(cid:2)110inchildren30-<96monthsoldvaccinatedwithaTIVorTIV,byprimingvaccine.Noneof
thesubjectwasvaccinatedwithseasonalorpandemicvaccinein2009.Childrenvaccinatedwithnon-influenzacontrolduringparentstudyonlyreceived
aTIVintheextensionstudy.
www.tandfonline.com HumanVaccines&Immunotherapeutics 2105
Antibodyresponsesbysubtype 13.1 fold rise. aTIV vaccinated children maintained a 2.7 fold
higher GMT compared to TIV vaccinated children at
H1N1
6 months. The GMT of the aTIV-aTIV group (925) was 7.7
Although subjects who received the 2009 pandemic vaccine
fold higher than the TIV-TIV group (120) at that point
were excluded from this analysis, baseline titers in all 3 groups
(Table 2).
suggested that pandemic exposure had occurred relatively uni-
formly in all groups, with geometric mean titers (GMTs) in the
rangeof33to59.Allgroupsrespondedwelltotheirfirstvaccina-
B
tionagainstA/California/07/2009(H1N1)irrespectiveofhaving
Baseline titers to the Victoria lineage B/Brisbane/60/2008
received adjuvanted, non-adjuvanted or no previous influenza
strainwereuniformlylowinallgroups,includingthosewhohad
vaccine in the earlier study, with 12.6 to 27.9 fold increases in
beenprimedwith2vaccinedosesin2008–2009,asthatformula-
response to aTIV and 9.7 to 24.2 fold increases in response to
tion contained a B/Yamagata lineage strain. The children who
TIV. Six months later, higher titers, in the range of 1.3 to 1.4
had been primed with TIV and were revaccinated with TIV
foldhigher,weremaintainedintheaTIV-comparedtoTIV-vac-
mounted a suboptimal response against the B/Victoria lineage
cinatedchildren(Table 2).
antigen from GMT 5 (pre-vaccination) to GMT 20 (Day 22
post-vaccination) and GMT 17 (Day 181 post-vaccination). In
H3N2 contrast, aTIV-primed children responded with at least 10-fold
Baseline antibody titers were 2.3 to 5.8 fold higher in chil- rises to the B/Victoria lineage antigen, achieving GMTs of 160
dren who had previously received aTIV compared to children and 95 on Day 22, whether they were revaccinated with adju-
who had been vaccinated originally with TIV. However, better vanted or non-adjuvanted vaccine, respectively, with persistence
persistence of the antibody-induced response in the aTIV- ofhigherGMTs(135and94)upto6 monthsfollowingvaccina-
primed group cannot be inferred because control children who tion. The six month GMT of the aTIV-aTIV group was almost
had not previously received influenza vaccine had evidence of 8-foldhigherthanthatoftheTIV-TIVgroup.Theresponsesof
baseline H3N2 antibodies at even higher levels, presumably the TIV-primed children were intermediate and reached a low
deriving from natural infection. Children primed with aTIV level of <40. In unprimed control subjects, who received aTIV
and those who had received control vaccines (and who had evi- in their first influenza vaccination, GMTs at Day 22 and 181
dence of natural infection) responded to aTIV with a 10.4 to were 74 and 178, respectively. Moderately high responses to the
14.3 fold rise to a GMT of~2200 at Day 22. Children who had B/Yamagata lineage strain following the initial 2 doses of adju-
been primed with TIV and then boosted with aTIV exhibited a vantedvaccineindicatedprimingfortheB/Victorialineageanti-
17.7foldrise,thoughtoalowerabsoluteGMTof1205astheir gen,whereasthiswasnotobservedfollowingprimaryvaccination
baseline titer after TIV priming was lower. The other mixed withTIV.AsinglevaccinationdoseofaTIVinthelattersubjects
regimen of aTIV followed by TIV produced an intermediate compensatedtosomedegreebutthecross-lineagetitersremained
rise of 4.5 fold to a GMT of 678, while successive TIV vaccina- lower than those in children primed with adjuvanted vaccine
tions produced the lowest GMT of 328, albeit as a result of a (Table 2).
Table2.GeometricmeantiterstovaccinestrainsatDays1,22and181inchildrenprimedwithaTIVorTIVcontainingA/Brisbane/59/2007(H1N1),A/Bris-
bane/10/2007(H3N2),andB/Florida/4/2006vaccineandsubsequentvaccinationin2010*
A/California/7/2009(H1N1) A/Perth/16/2009(A/H3N2) B/Brisbane/60/2008(Victoria)
Vaccinationstrains
Extensionstudyvaccine aTIV TIV aTIV TIV aTIV TIV
aTIVPrimed nD16 nD11–12 nD16 nD11–12 nD16 nD11–12
GMTDay1 59(27–131) 37(15–92) 157(68–358) 151(58–392) 8.4(5.1–14) 9.4(5.3–17)
GMTDay22 745(331–1676) 359(141–916) 2248(1622–3116) 678(465–989) 160(91–283) 95(49–183)
GMTDay181 320(147–695) 248(97–633) 925(619–1382) 341(210–553) 135(79–230) 94(49–179)
TIVPrimed nD21–23 nD12–14 nD21–23 nD12–14 nD21–23 nD12–14
GMTDay1 51(28–94) 33(15–72) 68(30–155) 26(8.9–74) 6.6(5.2–8.2) 5(3.7–6.7)
GMTDay22 1422(859–2356) 800(419–1527) 1205(749–1940) 328(178–604) 38(24–59) 20(11–36)
GMTDay181 417(263–661) 294(159–541) 331(171–640) 120(50–287) 31(16–58) 17(7.2–39)
Control nD10 nD10 nD10
GMTDay1 49(17–146) 211(69–647) 6.6(4.1–11)
GMTDay22 1613(570–4564) 2195(1097–4391) 74(14–386)
GMTDay181 343(147–802) 1114(707–1757) 178(56–565)
TIV:trivalentinactivatedinfluenzavaccines,aTIV:MF59adjuvantedTIV,Control(childrenhavenotbeenvaccinatedwithinfluenzavaccinepreviously),
GMT:geometricmeantiter.GMR:geometricmeanratio.Childrenvaccinatedwithnon-influenzacontrolduringparentstudyonlyreceivedaTIVintheexten-
sionstudy.
*Noneofthesubjectswerevaccinatedwithseasonalorpandemicvaccinein2009.
2106 HumanVaccines&Immunotherapeutics Volume11Issue8
Table3.6-<36months:Numberofsubjectsexperiencingsolicitedlocal*andsystemicreactionsoccurringwithinoneweekofvaccination,byprimingvac-
cine.Numberoflocalreactionsclassifiedassevereareshowninbrackets
aTIVPrimed TIVPrimed Control
Vaccinationvaccine aTIV(nD5) TIV(nD2) aTIV(nD2) TIV(nD0) aTIV(nD1)
Ecchymosis* 0 0 0 - 0
Erythema* 1(0) 1(0) 1(0) - 1(0)
Induration* 1(0) 0 0 - 0
Swelling* 0 1(0) 0 - 0
Tenderness* 4(0) 2(0) 0 - 1(0)
Changeineatinghabits 1 1 0 - 0
Sleepiness 2 0 1 - 1
Unusualcrying 3 0 0 - 0
Irritability 3 0 1 - 1
Vomiting 0 0 0 - 0
Diarrhea 2 0 0 - 0
Shivering 1 1 0 - 0
Fever(cid:2)37.3(cid:1)C 0 1 0 - 0
Fever(cid:2)39.3(cid:1)C 0 1 0 - 0
UseofAnalgesic/Antipyretics 1 1 0 - 0
TIV:trivalentinactivatedinfluenzavaccines,aTIV:MF59adjuvantedTIV,Control(childrenhavenotbeenvaccinatedwithinfluenzavaccinepreviously,they
onlyreceivedaTIVintheextensionstudy).Systemicreactionswereclassifiedaspresentornotpresent.
Safety age group following vaccination with TIV. In the age group 36-
Localandsystemicadversereactionsacrossthevaccinegroups, <96 months, the most common reported local reaction was
byprimingvaccinearesummarizedinTable 3(6-<36 months) injection site pain reported in 67% to 92% across vaccination
and Table 4 (36-<96 months). Overall, reactogenicity of aTIV groups.Therewerenoreportsofseverelocalreactions.Themost
wasslightlyhigherthanforTIV,thoughnottoamarkedorclini- commonly reported systemic reaction was fatigue, followed by
cally unacceptable extent. The majority of children reported at myalgia. There were 2 reports of severe systemic adverse events
least one reactogenicity sign post-vaccination. Reactions were (AEs) in subjects receiving aTIV (headache and malaise) and 1
transient and mostly mild to moderate in severity. In the 6- reportofseveresystemicAEinasubjectreceivingTIV(myalgia).
<36 months cohort, the most common reported local reaction Fever(cid:2)37.3(cid:1) Coccurredinupto14%ofsubjectsacrossgroups,
wastendernesswithnoreportsofseverereactions.Mostfrequent withnoreportsofseverefever.
reported systemic reactions were unusual crying and irritability. Spontaneously reported AEs were comparable across vaccine
There was one report of severe fever
(cid:2)39.3(cid:1)
C in the youngest groups, regardless of priming vaccine in the parent study or
Table4.36-<96months:Numberandpercentagesofsubjectsexperiencinganyandseveresolicitedlocal*andsystemicreactionsoccurringwithinone
weekofvaccination,byprimingvaccine
aTIVPrimed TIVPrimed Control
Revaccinationvaccine aTIV(nD12) TIV(nD10) aTIV(nD21) TIV(nD14) aTIV(nD9)
Ecchymosis*severe 1(8%)0 00 1(5%)0 1(7%)0 2(22%)0
Erythema*severe 7(58%)0 3(30%)0 10(48%)0 7(50%)0 4(44%)0
Induration*severe 5(42%)0 3(30%)0 2(10%)0 5(36%)0 2(22%)0
Swelling*Severe 6(50%)0 2(20%)0 2(10%)0 3(21%)0 2(22%)0
Pain*severe 11(92%)0 9(80%)0 15(71%)0 10(71%)0 6(67%)0
Chills/shiveringsevere 1(8%)0 00 2(10%)0 00 00
Malaisesevere 3(25%)0 00 4(19%)0 00 3(33%)1(11%)
Myalgiasevere 4(33%)0 00 4(19%)0 3(21%)1(7%) 1(11%)0
Arthralgiasevere 1(8%)0 00 3(14%)0 00 1(11%)0
Headachesevere 3(25%)1(8%) 1(10%)0 2(10%)0 2(14%)0 1(11%)0
Fatiguesevere 6(50%)0 2(20%)0 7(33%)0 4(29%)0 4(44%)0
Fever(cid:2)37.3(cid:1)Csevere(cid:2)39.3(cid:1)C 1(8%)0 00 3(14%)0 1(7%)0 2(22%)0
UseofAnalgesic/Antipyretics 1(8%) 0 4(19%) 1(7%) 3(33%)
TIV:trivalentinactivatedinfluenzavaccines,aTIV:MF59adjuvantedTIV,Control(childrenhavenotbeenvaccinatedwithinfluenzavaccinepreviously,they
onlyreceivedaTIVwithrevaccination),Feverwasclassifiedassevereif(cid:2)39.3(cid:1)C.
www.tandfonline.com HumanVaccines&Immunotherapeutics 2107
vaccination with aTIV or TIV. Overall, 59–75% of subjects Forexample,theelevatedbaselinetitersandresponsestothepan-
acrossgroupsexperiencedanyunsolicitedreaction,ofwhich17– demic H1N1 component in aTIV were similar, irrespective of
18%wasconsideredatleastpossiblyrelated.Onesubjectreceiv- whether the children had been primed with aTIV, TIV or had
ingaTIVexperiencedaseriousadverseevent(SAE)(snakebite), hadnopriorinfluenzavaccinationatall.Theuniformlyelevated
considered as not related to study vaccination. There were no baseline titers in all subjects suggested similar experiences with
deathsandnoAEsleadingtoprematurestudydiscontinuation. thepandemicinfectioninallgroupsandbecausethe2008–2009
In the subpopulation of children that received pandemic influenza vaccine contained an H1N1 strain that was so highly
AS03-adjuvanted vaccine in 2009, similar trends were observed divergentfromthepandemicH1N1strain, itprovided noaddi-
forimmunogenicityandsafetyoutcomes(Tables S1andS2). tional detectable priming to the naturally-acquired pandemic
infection upon H1N1pnd09 immunisation.19,20 Those titers
were »2-fold higher in the aTIV compared with TIV recipients
Discussion irrespective of priming history, demonstrating the impact of the
adjuvant. However, the sample sizes were small and the confi-
Routine influenza vaccination in children, beginning at denceintervalsbetweenaTIVandTIVoverlapped,thereforethe
6 months of age, is increasingly recommended as children and differencewasnotsignificant.
infantsexperiencethehighestratesofseasonalinfluenzainfection A similar but more complex pattern was seen in response to
and hospitalisation.1-4 We previously showed in a head to head the H3N2 antigen against which the aTIV-primed children,
trial in vaccine-na€ıve 6–71 month old children that aTIV was and the control children who received aTIV for the first time
86% efficacious in preventing PCR-confirmed influenza, com- had similarly elevated baseline and post-vaccination responses
pared with 42% for TIV.11 Moreover, aTIV was efficacious in to the H3N2 antigen. It is not possible to discriminate
every age subgroup (96% in 36–71 months olds, 81% in 6– whether the elevated baseline titer in the aTIV group may
35 monthsolds,and75%in6–23 monthsolds)atefficacyrates have reflected a declining antibody titer from vaccination
thatareintherangeexpectedforaroutinelyadministeredchild- 2 years earlier or an intervening H3N2 infection or both.
hoodvaccine.11TheMF59-adjuvantedvaccinewasalsowelltol- These responses were higher than in the other groups. In the
erated and in an integrated analysis of 1181 children who TIV-aTIV children poorer persistence of antibody after prim-
received aTIV in clinical trials no pattern of associated serious ing and, possibly, a lower rate of naturally acquired infection
AEs was demonstrated.16 Because influenza vaccine must be in the intervening year (reflected in a lower baseline GMT)
administeredannually,ifaTIVwastobeusedinnationalsched- led to an intermediate response to the vaccination with aTIV.
ules,dataonitsimmunologicaladvantageaswellasitstolerabil- In contrast, vaccination with TIV in the aTIV-TIV group led
ityandsafetyuponrepeatedvaccinationareneeded. to a lower GMT response, though the group had a similar
Herewereporttheresultsofanextensionstudyofvaccination baseline antibody titer, indicating again, the impact of the
with aTIV versus TIV in children now aged 30–96 months, adjuvant in the vaccination vaccine. Finally, the TIV-TIV
whose only influenza vaccination had been in the previous effi- group, whose baseline titers were the lowest, had the lowest
cacy trial 2 years earlier. The 2009 pandemic prevented us from response to vaccination.
assessingthevaccination responseintheseasonimmediatelyfol- The response to the B/Victoria lineage antigen in the second
lowing the efficacy trial. To examine the immune responses of year vaccination (while the first vaccine contained a B/Yamagata
vaccinationinthefirstfollow-upseasonalvaccinationafterprim- lineage antigen) showed that aTIV primed with the B/Yamagata
ing,weexcludedallsubjectswhoreceivedeitherseasonalorpan- lineage antigen boosted the secondary antibody response against
demic vaccination in 2009 from the study analyses. Therefore, the opposing lineage (GMTs 160 for aTIV, 95 for aTIV-TIV),
only small datasets could be analyzed, which should be taken whereas, as noted previously, TIV did not (GMTs 38 for TIV-
intoconsiderationininterpretingtheresults. aTIV and 20 for TIV-TIV).21 However, as cross priming in the
The results of this study demonstrate that the aTIV-aTIV other direction was not studied, it would be inappropriate to
sequenceproduced6.8-foldand8-foldhigherantibodyresponses speculateaboutcross-lineageresponsesingeneral.Thecross-line-
to A/H3N2 and B strains, respectively, than the reference TIV- age priming associated with aTIV, though of great interest, is
TIV regimen (referring to the vaccination given in the efficacy perhaps moot from a public health perspective, as quadrivalent
study and the current study, respectively), but not to A/H1N1 formulations containing antigens from both B lineages are
strain.Also,forA/H3N2andBstrains,primaryvaccinationwith becoming the new standard for children. We also reconfirmed
aTIV was found to be more immunogenic than 2 consecutive the phenomenon of original antigenic sin – at least in the direc-
vaccinationswithTIV. tionofstrongerresponsestoafirstexposuretoB/Yamagataanti-
The magnitude of the difference between aTIV-aTIV and gen–withstrongerresponsestotheprimingB/Yamagatalineage
TIV-TIVregimenwasespeciallyimportantforinfluenzaBwhere antigen that had been administered 2 years earlier, compared to
TIV-TIV provided only a GMT of 20 (Day 22) in the second theresponsetothemorerecentlyadministeredB/Victorialineage
year while for aTIV-aTIV, the GMT response on Day 22 was antigen.22,23
160. For the mixed regimens of aTIV-TIV or TIV-aTIV, the The maintenance of elevated antibodies at high levels for
advantage of aTIV in the second year varied with viral subtype, 6 months by the regimen of repeated aTIV administration is of
as inferred from elevated baseline GMTs to that viral subtype. practical importance as annual vaccination campaigns in the
2108 HumanVaccines&Immunotherapeutics Volume11Issue8
Northern Hemisphere now begin in August while the peak immunity but not shown to bias the immune response in chil-
monthofinfluenzatransmissionisinFebruary.24Andinareasof drentowardTh1orTh2.39-40
theworldwhereinfluenzaviraltransmissionissustainedforlon- Altogether, within the limitations of a small study, the
ger intervals or maintained throughout the calendar year, anti- strong immune responses and adequate safety profile of aTIV
bodies induced by a single annual vaccination ideally would support the use of such vaccines for annual vaccination in
persistatprotectivelevelsforuptoayear.25 young children, beginning at 6 months of age. Ultimately, a
The lower absolute levels of HI antibodies to the vaccine- study starting at 6 months of age followed by annual vaccina-
matched and variant B strains, compared with the A subtype tions using either aTIV or TIV should be designed to prove
responsesshouldbeinterpretedinthecontextofthelowsensitiv- this assumption.
ityoftheHIassayindetectingantibodiestotheBvaccinecom-
ponent.26 Compared to HI test results, neutralizing antibody
Methods
titers elicited by the inactivated vaccine generally are higher and
areequallyhighforBandAcomponents.27,28
Vaccination with aTIV produced slightly higher but accept- Studydesign
able local and systemic reactogenicity compared with repeated This Phase 3b, randomized, observer-blind, pediatric exten-
TIV vaccination, while the mixed regimens of aTIV-TIV and sionstudywasperformedat15sitesacrossFinlandfromSeptem-
TIV-aTIV were similar to the “reference” TIV-TIV regimen in ber 2010 until January 2011 (ClinicalTrials.gov identifier:
terms of thepattern and frequencyof local and systemic adverse NCT01210898).TheprotocolwasapprovedbytheEthicsCom-
events.ForunsolicitedAEs,thepatternandfrequencyweregen- mitteeofthePirkanmaaHospitalDistrict,andthestudywasper-
erally similar between groups. There were no vaccine-related formedaccordingtotheprinciplesoftheDeclarationofHelsinki
SAEs. Prior to the study, there were concerns of enhanced AEs andGoodClinicalPractice.Beforeenrollment,writteninformed
following revaccination one year following the original study, or consentwasobtainedfromallparents/legalguardians.
whenthesimilarantigenicstrainswereusedinthesecondround
of vaccinations. However, enhanced reactivity was not observed. Objective
Thus,withinthelimitedexperienceofthisstudywithsmalldata In the previously reported efficacy study (ClinicalTrials.gov:
sets,theconsiderablyhigherantibodytitersachieveduponvacci- NCT01015885)greaterimmunogenicityandefficacyweredem-
(cid:1)
nation with aTIV, with a minor increase in reactogenicity, pro- onstrated for aTIV over split TIV (Influsplit SSW , GlaxoS-
videsabenefit:riskthatmightbejustifiable.29 mithKline Biologicals) in children aged 6-<72 months in
Higher antibody titers are needed in young children to 2008–2009.11Themainobjectiveofthisextension studywasto
produce levels of efficacy seen in adults at lower titers of evaluatetheimmunogenicityfollowingvaccinationwithaTIVor
»40. In the efficacy study prior to this follow-up, we showed subunit TIV administered as age-dependent full or half doses in
that an HI titer of 110 was correlated with a vaccine efficacy 2010–2011 according to the criteria defined by the European
of 50%, and 330 with a clinical efficacy of 80% against the
CHMPandUS.CBER.41,42Allsubjectswhoreceivedeithersea-
circulating H3N2 strain,12 although this needs to be con- sonal or monovalent pandemic vaccine in 2009 were excluded
firmed in other studies. The demonstration that an HI titer from the analyses. Additional objectives were to assess antibody
of 40 correlated with 50% protection in children 6–17 years persistenceat6 monthsfollowingvaccinationandtoevaluatethe
of age supports an age threshold within this range when a reactogenicityandsafetyprofilesforeachvaccine.SAEswerecol-
majority of children will have been primed – consistent with lectedupto1 yearpostvaccination.
recommendations in the US that children under 9 years of Of those subjects receiving pandemic vaccination in 2009
(cid:1)
age need 2 doses in their first season of vaccination in order (AS03-adjuvanted containing vaccine Pandemrix , GSK), safety
to prime them.30 Thus the greater reliance on antibodies for and immunogenicity against A/H1N1 strain were added as sup-
protection provided by the inactivated vaccine in young chil- plementarydata
dren favors the annual use of aTIV starting at 6 months and
through an undefined age, probably in the interval between 6 Subjects
and 9 years of age. Eligible study participants were healthy children who had
The impact of influenza vaccination on T-cell immunity in received2dosesofatleast1ofthestudyvaccinesintheprevious
children,anddifferenceselicitedbyinactivatedvs.liveattenuated parent trial and whose parents/legal guardians had given prior
vaccine, are currently important topics in the field of influenza written informed consent. Principal exclusion criteria included
vaccine development. Some investigators have proposed that any history or ongoing (chronic) illness likely to interfere with
TIV vaccination of children may prevent the induction of a theresults;hypersensitivitytovaccinecomponents;receiptofany
broad cellular immune response, which could place them at othervaccine<2 weeks(forinactivatedvaccines)or4 weeks(for
greater risk for pandemic influenza infection, although clinical livevaccines)priortoenrollmentinthisstudyorwhowereplan-
evidenceforthisinthe2009pandemicwasunclear.31-38 ning to receive any vaccine <4 weeks from the study vaccine;
One limitation of this study was thattherewasno possibility participation in any clinical trial with another investigational
to investigate the impact of aTIV on cellular immunity, product30 daysprior tothefirststudy visit or intention to par-
although, in other studies, MF59 is known to stimulate T-cell ticipate in another clinical study at any time during theconduct
www.tandfonline.com HumanVaccines&Immunotherapeutics 2109
of this study; antibiotics <6 days before vaccination; axillary the percentage of subjects per group achieving at least a 4-fold
temperature (cid:2)37.3(cid:1) C within 3 days prior to the first visit, and increaseinHItiterfromaseropositiveprevaccinationtiter((cid:2)10)
receiptofblood,bloodproductsand/orplasmaderivativeorany orarisefrom<10to(cid:2)40inthosewhowereoriginallyseronega-
parenteral immunoglobulin preparation in the previous tive.PercentagesofsubjectswithHItiters(cid:2)110werealsocalcu-
12 weeks. lated, as this cut-off titer was shown in one analysis to predict a
50% clinical protective level in young children, compared with
Studyprocedures the conventional HI titer of (cid:2)1:40 associated with 50% protec-
In the original efficacy study, subjects were primed in 2008– tionofyoungadults.12
09 with 2 age-appropriate doses of TIV, aTIV or noninfluenza
control vaccine (Control) vaccines (meningococcal C conjugate
(cid:1) Safetyassessment
[Menjugate , Novartis Vaccines] or tickborne encephalitis vac-
(cid:1) Subjects were monitored for 30 minutes after each vaccina-
cines [Encepur Children , Novartis Vaccines]). In this study,
tion for possible immediate adverse reactions. Parents/legal
aTIV-andTIV-primedchildrenwerere-randomizedtoberevac-
guardians were unaware of the study vaccine administered to
cinated with either aTIV or TIV. Children aged <36 months
their children and were instructed to complete diary cards to
were randomized 1:1 to receive half a dose (0.25mL) of TIV or
record specified local and systemic reactions for 7 days, starting
aTIV; children (cid:2)36 months of age were randomized 1:1:1 to
on the day of vaccination. Solicited local reactions included
receiveafulldose(0.5mL)ofTIV,orahalforfulldoseofaTIV.
ecchymosis,erythema,induration,swellingandtenderness(chil-
Influenza vaccine-na€ıve control subjects previously vaccinated
dren <36 months) or ecchymosis, erythema, induration, swell-
withcontrolnoninfluenzareceivedhalfadoseofaTIV(children
ing and pain at injection site (children (cid:2)36 months). Solicited
<36 months), or were randomized 1:1 to receive half or full
systemicreactionsweresleepiness,diarrhea,vomiting,irritability,
doseofaTIV(childrenaged(cid:2)36 months).Becausethenumbers
change in eating habits, shivering, and unusual crying (children
ofsubjectsinthesedosesubgroupsweresosmall,theywerecom-
<36 monthsofage),orchills,malaise,myalgia,arthralgia,head-
binedwithineachtreatmentarmforthispaper.
acheandfatigue(children(cid:2)36 monthsofage).Otherindicators
Bloodsamples(5 mLpersample)wereobtainedforimmuno- ofreactogenicitywerefever(axillarytemperature(cid:2)37.3(cid:1)
C)and
genicity analyses at baseline (Day 1, prevaccination), 3 weeks
useofanalgesics/antipyreticmedication.ReportsofanyAEswere
after vaccination (Day 22), and approximately 6 months (Day
recordedfromDay1toDay22,SAEsandAEsleadingtostudy
181)afterimmunization.
withdrawal were recorded throughout the study period. The
severity of AEs was categorized as mild, moderate, or severe, if
Vaccines
they resulted in no limitation, some limitation, or inability to
aTIV and TIV each contained 15 mg of hemagglutinin anti-
perform normal daily activities, respectively. Assessments of the
gen from each of the 3 World Health Organization recom-
causal relationship of unsolicited AEs to the vaccination were
mended influenza strains for the 2010–2011 influenza season in
classified by the investigator as not related, possibly related, or
the northern hemisphere: A/ California/7/2009 (H1N1), A/
probablyrelated.
Perth/16/2009(H3N2)andB/Brisbane/60/2008(Victoria).
AstandarddoseoftheadjuvantMF59,asusedinone0.5-mL
dose of the commercially available seasonal influenza vaccine Statisticalanalyses
Fluad, contains 9.75 mg squalene, 1.175 mg polysorbate 80, CHMPhasnotestablishedinfluenzavaccineimmunogenicity
1.175 mg sorbitan trioleate, 0.66 mg sodium citrate, 0.04 mg criteria for children so those used for young adults were refer-
citric acid, and water for injection. Vaccines were supplied in enced:thepercentageofsubjectsachievingseroconversionforHI
monodose, prefilled syringes filled with 0.5 mL with a pediatric antibody should be >40%; the percentage of subjects achieving
mark at 0.25mL for administration in subjects <36 months. HIantibodytiter(cid:2)40%shouldbe>70%andtheGMRshould
The vaccine formulations were prepared and administered by be>2.5.42ImmunogenicitywasalsoanalyzedusingCBERcrite-
unblindedstudypersonnel,whootherwisedidnotparticipatein ria:thelowerboundofthe2-sided95%confidenceinterval(CI)
evaluation of the subjects during the study. The vaccines were for the percent of subjects achieving seroconversion for HI anti-
administered intramuscularly in the deltoid muscle preferably of body should be (cid:2)40% (seroconversion criterion); and the lower
thenon-dominantarm. boundof the2-sided 95%CI for thepercentof subjects achiev-
ing an HI antibody titer (cid:2)40 should be (cid:2)70% (seroprotection
Immunogenicityassessment criterion).41 Percentages of subjects with HI titers (cid:2)110 were
Bloodsamplestakenforimmunologicassaysweretestedatthe also calculated. Log -transformed antibody titers were modeled
10
Novartis Vaccines Clinical Serology Laboratory in Marburg, using analysis of variance for each strain, and GMTs, GMRs,
Germany, for HI antibody responses to strains contained in the and corresponding 2-sided 95% CI were calculated. Safety data
vaccine (vide supra). HI antibody responses on Days 1, 22, and were evaluated descriptively and expressed as the percentage or
181 were expressed as GMTs, GMRs of the postvaccination to number of subjects with AEs in each group. Immunogenicity
prevaccination titer (Day 22/Day 1 titer and Day 181/Day 1 analyses were conducted on the full analyses set (FAS), which
titer);seroprotectionratesweredefinedasthepercentageofsub- consistedofsubjectswhoreceivedthestudyvaccineandprovided
jectswithHItiters(cid:2)40,andseroconversionratesweredefinedas atleastoneevaluableserumsamplebeforeandaftervaccination.
2110 HumanVaccines&Immunotherapeutics Volume11Issue8
Safetywasanalyzedforallsubjectsexposedtostudyvaccineswho (independent Medical Writer, CtrlP), Shanthi Voorn and
providedatleast1safetydatapoint. Keith Veitch for providing editorial assistance in the prepara-
tion of this manuscript.
DisclosureofPotentialConflictsofInterest
T.V.hasreceivedconsultingfeesorhonoraria,travelsupport,
andfeesforparticipationinreviewactivities fromNovartisVac-
Authos’Contributions
cines and Diagnostics, Inc.. T.V. has also received consultancy
fees from GlaxoSmithKline PLC, Merck & Co., Inc.., MedI- All authors participated in the conception, design and imple-
mmune LLC, SanofiPasteur MSD, and Novartis Vaccines and mentationofthetrials.Allauthorswereinvolvedintheinterpreta-
Diagnostics, Inc.. A.F. has no conflicts of interest to disclose. A. tionofanalyzeddataandthedecisiontosubmitforpublication.
A., T.T. and R.C. are or were employees of Novartis Vaccines
andDiagnostics,Inc.duringthetimeofthestudy.
Acknowledgments SupplementalMaterial
The authors are grateful to all the volunteers who partici- Supplemental data for this article can be accessed on the
pated in the clinical trial, and thank Patricia de Groot publisher’s website.
References PMID:17301299; http://dx.doi.org/10.1056/NEJMoa 19. MelonK,PartinenM,TynellJ,Sillanp€a€aM,Himanen
1. PanAmericanHealth Organization Immunizationin 065368 S-L,Saarenp€a€a-Heikkil€aO,HublinC,OlsenP,Ilonen
the Americas. 2013 Summary. PAHO. Washington 11. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kie- J,NohynekH,etal.NoserologicalEvidenceofInflu-
DC2013,1–12. ninger-BaumD,SchmittHJ,BaehnerF,BorkowskiA, enzaAH1N1pdm09VirusInfectionasaContributing
2. FioreAE,UyekiTM,BroderK,FinelliL,EulerGL, TsaiTF,ClemensR.Oil-in-wateremulsionadjuvant FactorinChildhoodNarcolepsyAfterPandemrixVac-
SingletonJA,IskanderJK,WortleyPM,ShayDK,Bre- with influenza vaccine in young children. N Engl J cinationCampaigninFinland.PlosOne2013;8(8):
seeJS,etal.Preventionandcontrolofinfluenzawith Med 2011;365(15):1406–16; PMID:21995388; e68402;PMID:23950869;http://dx.doi.org/10.1371/
vaccines:recommendationsoftheAdvisoryCommittee http://dx.doi.org/10.1056/NEJMoa1010331 journal.pone.0068402
on Immunization Practices (ACIP), 2010. MMWR 12. BlackS,NicolayU,VesikariT,KnufM,DelGiudice 20. Lyytik€ainenO,KuusiM,ToikkanenM,VirtanenM,
2010;59(RR-8):1–62;PMID:20689501
G,DellaCioppaG,TsaiT,ClemensR,RappuoliR. R€onkk€oE,StrengellM,etal.Thesurveillanceresults
3. Ropero-Alvarez AM, Kurtis HJ, Danovaro-Holliday Hemagglutinationinhibitionantibodytitersasacorre- of the second wave of 2009 pandemic influenza A
MC,Ruiz-MatusC,AndrusJK.Expansionofseasonal lateofprotectionforinactivatedinfluenzavaccinesin (H1N1) in Finland, November 2010-April 2011.
influenza vaccination in the Americas. BMC Pub
children. Pediatr Infect Dis J 2011;30(12):1081–5; L€a€ak€arilehti2011;40:2925–2930(EnglishSummary)
Health 2009;9:361; http://dx.doi.org/10.1186/1471- PMID:21983214; http://dx.doi.org/10.1097/INF. 21. Walter EB, Neuzil KM, Zhu Y, Fairchok MP,
2458-9-361 0b013e3182367662 GaglianoME,MontoAS,EnglundJA.Influenzavac-
4. ZhouH,ThompsonWW,ViboudCG,RingholzCM, 13. AnsaldiF,ZancolliM,DurandoP,MontomoliE,Stic- cineimmunogenicityin6-to23-month-oldchildren:
Cheng PY, Steiner C, Abedi GR, Anderson LJ, chi L, Del Giudice G, Icardi G. Antibody response areidenticalantigensnecessaryforpriming?Pediatrics
BrammerL,ShayDK.Hospitalizationsassociatedwith againstheterogeneouscirculatinginfluenzavirusstrains 2006;118(3):e570–8; PMID:16950948;http://dx.doi.
influenzaandrespiratorysyncytialvirusintheUnited elicitedbyMF59-andnon-adjuvantedvaccinesduring org/10.1542/peds.2006-0198
States, 1993–2008. Clin Infectious Dis 2012;54 seasonswithgoodorpartialmatchingbetweenvaccine 22. SkowronskiDM,HamelinME,JanjuaNZ,DeSerres
(10):1427–36;http://dx.doi.org/10.1093/cid/cis211 strainandclinicalisolates.Vaccine2010;28(25):4123– G,GardyJL,RheaumeC,BouhyX,BoivinG.Cross-
5. Centers for Disease Control and Prevention. 2010– 9; PMID:20433807; http://dx.doi.org/10.1016/j. lineageinfluenzaBandheterologousinfluenzaAanti-
2011InfluenzaSeasonSummery.http://www.cdc.gov/ vaccine.2010.04.030 bodyresponsesinvaccinatedmice:immunologicinter-
flu/weekly/weeklyarchives2010–2011/10–11summary. 14. O’HaganDT,RappuoliR,DeGregorioE,TsaiT,Del actionsandB/Yamagatadominance.PloSOne2012;7
html.Accessed22April2014. GiudiceG.MF59adjuvant:thebestinsuranceagainst (6):e38929; PMID:22745690; http://dx.doi.org/
6. WongKK,JainS,BlantonL,DharaR,BrammerL, influenza strain diversity. Exp Rev Vacc 2011;10 10.1371/journal.pone.0038929
FryAM,FinelliL.Influenza-associatedpediatricdeaths (4):447–62;http://dx.doi.org/10.1586/erv.11.23 23. SkowronskiDM,HottesTS,DeSerresG,WardBJ,
intheUnitedStates,2004–2012.Pediatrics2013;132 15. Vesikari T, Forsten A, Borkowski A, Gaitatzis N, JanjuaNZ,SabaiducS,ChanT,PetricM.Influenza
(5):796–804; PMID:24167165; http://dx.doi.org/ Banzhoff A, Clemens R. Homologous and heterolo- Beta/Victoria antigen induces strong recall of Beta/
10.1542/peds.2013-1493 gousantibodyresponsestoaone-yearboosterdoseof YamagatabutlowerBeta/Victoriaresponseinchildren
7. AmbroseCS,WuX,KnufM,WutzlerP.Theefficacy an MF59((R)) adjuvanted A/H5N1 pre-pandemic primedwithtwodosesofBeta/Yamagata.PediatrInfect
ofintranasalliveattenuatedinfluenzavaccineinchil- influenza vaccine in pediatric subjects. Hum Vaccin DisJ2011;30(10):833–9;PMID:21857263;http://dx.
dren2through17yearsofage:ameta-analysisof8 Immunother 2012;8(7):921–8; PMID:22777094; doi.org/10.1097/INF.0b013e31822db4dc
randomized controlled studies. Vaccine 2012;30 http://dx.doi.org/10.4161/hv.20248 24. CenterofDiseaseControlandPrevention(CDC):Key
(5):886–92; PMID:22155144; http://dx.doi.org/ 16. BlackS,DellaCioppaG,MalfrootA,NacciP,Nicolay facts about seasonal flu vaccine. http://www.cdc.gov/
10.1016/j.vaccine.2011.11.104 U, Pellegrini M, Sokal E, Vertruyen A. Safety of flu/protect/keyfacts.htm
8. DiazGranadosCA,DenisM,PlotkinS.Seasonalinflu- MF59-adjuvantedversusnon-adjuvantedinfluenzavac- 25 DurandoP,IudiciR,AlicinoC,AlbertiM,deFlorentis
enzavaccineefficacyanditsdeterminantsinchildren cinesinchildrenandadolescents:anintegratedanalysis. D,AnsaldiF,IcardiG.Adjuvantsandalternativeroutes
andnon-elderlyadults:asystematicreviewwithmeta- Vaccine 2010;28(45):7331–6; PMID:20813217; ofadministrationtowardsthedevelopmentoftheideal
analyses of controlled trials. Vaccine 2012;31(1):49– http://dx.doi.org/10.1016/j.vaccine.2010.08.075 influenza vaccine. Hum Vacc 2011; 7 Suppl: 29–40;
57; PMID:23142300; http://dx.doi.org/10.1016/j. 17. PellegriniM,NicolayU,LindertK,GrothN,Della http://dx.doi.org/10.4161/hv.7.0.14560
vaccine.2012.10.084 Cioppa G. MF59-adjuvanted versus non-adjuvanted 26. Katz JM, Hancock K, Xu X. Serologic assays for
9. OsterholmMT,KelleyNS,SommerA,BelongiaEA. influenza vaccines: integrated analysis from a large influenzasurveillance,diagnosisandvaccineevalua-
Efficacyandeffectivenessofinfluenzavaccines:asys- safety database. Vaccine 2009;27(49):6959–65; tion. Exp Ref Anti-Infect Ther. 2011;9(6):669–83;
tematic review and meta-analysis. Lancet Infect Dis PMID:19751689;http://dx.doi.org/10.1016/j.vaccine. PMID:21692672
2012;12(1):36–44; PMID:22032844; http://dx.doi. 2009.08.101 27. KatzJ,KancockK,VeguillaV,ZhongW,LuXH,Sun
org/10.1016/S1473-3099(11)70295-X 18. NohynekH,JokinenJ,PartinenM,VaaralaO,Kirja- H,etal.Serumcross-reactive antibodyresponsetoa
10. B Re El ,sh He uR lB tq, uE id stw Mard ,s KK eM mb, lV ee Gsik ,a Cri oT n, nB ol rac Ek MSV ;C,W AIa Vlk -e Tr v na ei nne In ,OT l, s(cid:1)eS nun Pd ,m eta an l.J A, SH 0i 3m aa dn je un vaS nL te, dH Au Hbl 1in NC 1, vJ au cclk inu e- n seo av se ol ni an lflu ine fln uza enA za(H v1 acN ci1 n) e.vir Mus Maf Wter Rva 2c 0ci 0n 9a ;tio 5n 8(w 19it )h
:
Comparative Efficacy Study Group. Live attenuated associatedwithanabruptincreaseintheincidenceof 521–4;PMID:19478718
versus inactivated influenza vaccine in infants and childhoodnarcolepsyinFinland.PloSOne2012;7(3): 28. MontomoliE,CapecchiB,HoschlerK.Correlatesof
youngchildren.NEnglJMed2007;356(7):685–96; e33536;PMID:22470453;http://dx.doi.org/10.1371/ protectionagainstinfluenza.In:Influenzavaccinesfor
journal.pone.0033536
www.tandfonline.com HumanVaccines&Immunotherapeutics 2111
the future, 2nd edition. Rappuoli R, del Giudice G Virol 2010; 91 (7): 1743–53; PMID:20335492; T-cellimmunitytotheH7N9influenzaAvirusvaries
(eds).2011.Springer,Basel http://dx.doi.org/10.1099/vir.0.020784-0 acrossethnicities.ProcNatlAcadSciUSA2014;111
29 BanzhoffA,StoddardJ.Effectiveinfluenzavaccinesfor 34. SridharS,BegomS,BerminghamA,HosclerK,Adam- (3):1049–54; http://dx.doi.org/10.1073/pnas.
children. Acritical unmet medical need and apublic sonW,CarmanW,BeanT,BarclayW,DeeksJJ,Lal- 1322229111
healthpriority.HumVaccinImmunother.2012;8(3): vani A. Cellular immune correlates of protection 39. CoulterA,WongTY,DraneD,BatesJ,MacfarlanR,
398–402; PMID:22327501; http://dx.doi.org/ against symptomatic pandemic influenza. Nat Med Cox J. Studies on experimental adjuvanted influenza
10.4161/hv.18561 2013; 19(10):1305–12; PMID:24056771; http://dx. vaccines:comparisonofimmunestimulatingcomplexes
30. NgS,FangVJ,IpDK,ChanKH,LeungGM,Peiris doi.org/10.1038/nm.3350 (Iscoms)andoil-in-watervaccines.Vaccine1998;16
JS,CowlingBJ.Estimationoftheassociationbetween 35. Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier (11–12):1243–53;PMID:9682385;http://dx.doi.org/
antibodytitersandprotectionagainstconfirmedinflu- RA,OsterhausAD,RimmelzwaanGF.Cross-recogni- 10.1016/S0264-410X(98)80125-4
enzavirusinfectioninchildren.JInfectDis.2013;208 tionofavianH5N1influenzavirusbyhumancytotoxic 40. ZeddaL,Forleo-NetoE,VertruyenA,RaesM,March-
(8):1320–4; PMID:23908481; http://dx.doi.org/ T-lymphocytepopulationsdirectedtohumaninfluenza ant A,Jansen W,Clouting H,Arora A,Beatty ME,
10.1093/infdis/jit372 Avirus.JVirol2008;82(11):1598–606;http://dx.doi. Galli G, etal. Dissecting the Immune Response to
31. Bodewes R, Fraaij PL, Geelhoed-Mieras MM, van org/10.1128/JVI.02694-07 MF59-adjuvantedandNonadjuvantedSeasonalInflu-
BaalenCA,TiddensHA,vanRossumAMvanderKlis 36. vandeSandtCE,KreijtzJH,deMutsertG,Geelhoed- enzaVaccinesinChildrenLessThanThreeYearsof
FR,FouchierRA,OsterhausAD,RimmelzwaanGF. MierasMM,HillaireML,VogelzangvanTrierumSE, Age. Pediatr Infect Dis J 2015; 34(1):73–8;
Annual vaccination against influenza virus hampers Osterhaus AD, Fouchier RA, Rimmelzwaan GF. PMID:25037034; http://dx.doi.org/10.1097/INF.
developmentofvirus-specificCD8CTcellimmunity HumancytotoxicTlymphocytesdirectedtoseasonal 0000000000000465
in children. J Virol 2011; 85(22): 11995–20000; influenzaAvirusescross-reactwiththenewlyemerging 41. FDAFoodandDrugAdministration.Guidancefor
PMID:21880755; http://dx.doi.org/10.1128/JVI. H7N9 virus. J Virol 2014; 88(3):1684–93; Industry: Clinical Data Needed to Support the
05213-11 PMID:24257602; http://dx.doi.org/10.1128/JVI. Licensure of Seasonal Inactivated Influenza Vac-
32. Bodewes R, Kreijtz RH, Rimmelzwaan GF. Yearly 02843-13 cines. May 2007. http://www.fda.gov/downloads/
influenzavaccinations:a double-edged sword? Lancet 37. LeeLY,HadoLA,SimmonsC,deJongMD,Chau BiologicsBloodVaccines/GuidanceComplianceRegu
Infect Dis 2009; 9(12):784–8; PMID:19879807; NV,SchumacherR,PengYC,McMichaelAJ,Farrar latoryInformation/Guidances/Vaccines/ucm091985.
http://dx.doi.org/10.1016/S1473-3099(09)70263-4 JJ, Smith GL, etal. Memory T cells established by pdf.Accessed22April2014
33. BodewesR,KreijtzK,HillaireML,Geelhoed-Mieras seasonal human influenza A infection cross-react 42. TheCommitteeforProprietaryMedicinalProducts
MM,FouchierRA,OsterhausAD,RimmelzwaanGF. withavianinfluenzaA(H5N1)inhealthyindividu- (CHMP). Note for guidance on hamonisation of
Vaccinationwithwholeinactivatedvirusvaccineaffects als. J Clin Invest 2008; 118(10):3478–90; requirementsforinfluenzavaccines.CHMP/BWP/
the induction of heterosubtypic immunity against PMID:18802496 214/96. Available at: http://www.ema.europa.eu/
influenza virus A/H5N1 and immunodominance of 38. Quin~ones-Parra S, Grant E, Loh L, Nguyen TH, docs/en_GB/document_library/Scientific_guideline/
virus-specific CD8CT-cellresponses inmice.JGen Campbell KA, Tong SY, Miller A, Doherty PC, 2009/09/WC500003945.pdf Accessed 22 April
VijaykrishnaD,RossjohnJ,etal.Pre-existingCD8C 2014
2112 HumanVaccines&Immunotherapeutics Volume11Issue8
